The levels of Ang II have been found to be elevated in optimally treated (using ACE blockers or ARB) patients of heart failure, thus adding to the adverse health effects (Jorde et al., 2000; Petrie et al., 2001; Li et al., 2004; Patel et al., 2016). Here, ACE is linked to heart failure.